Orchid Pharma's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 101.34.
Orchid Pharma's Days Inventory for the
three
months ended in Mar. 2026 was 154.58.
Orchid Pharma's Days Payable for the
three
months ended in Mar. 2026 was 138.6.
Therefore, Orchid Pharma's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 117.32.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Orchid Pharma Cash Conversion Cycle Related Terms
Orchid Pharma Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Orchid Pharma's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LUX:ORCHP vs ZTS, UTHR: Cash Conversion Cycle Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Orchid Pharma's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Orchid Pharma Cash Conversion Cycle vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Orchid Pharma's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Orchid Pharma's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Orchid Pharma's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orchid Pharma (LUX:ORCHP) has a Cash Conversion Cycle of 117.32 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Orchid Pharma and its competitors.
Is Orchid Pharma's Cash Conversion Cycle too high?
Orchid Pharma's current Cash Conversion Cycle is 117.32. The Drug Manufacturers industry median Cash Conversion Cycle is 145.82. Orchid Pharma's value of 117.32 is 19.5% below this industry median. Overall, Orchid Pharma has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Orchid Pharma's Cash Conversion Cycle compare to ZTS and UTHR?
Orchid Pharma's Cash Conversion Cycle of 117.32 can be compared against companies in the Drug Manufacturers industry. The industry median Cash Conversion Cycle is 145.82. Orchid Pharma's value of 117.32 is 19.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Drug Manufacturers company?
The median Cash Conversion Cycle among Drug Manufacturers companies is 145.82, based on 949 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Orchid Pharma's current Cash Conversion Cycle of 117.32 is 19.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Orchid Pharma and its competitors. For the Drug Manufacturers industry, the median Cash Conversion Cycle is 145.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Orchid Pharma's current Cash Conversion Cycle is 117.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Orchid Pharma stock overvalued right now?
Orchid Pharma (LUX:ORCHP) has a current Cash Conversion Cycle of 117.32. The stock's GF Value™ is $4.60, compared to a current price of $5.45 — trading 18.5% above its estimated fair value. The current Cash Conversion Cycle is 117.32 and 19.5% below the Drug Manufacturers industry median of 145.82. Orchid Pharma's overall GF Score™ is 60/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Orchid Pharma (LUX:ORCHP), the current Cash Conversion Cycle is 117.32 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Orchid Pharma (LUX:ORCHP) Overvalued in 2026?
Based on GuruFocus' analysis, Orchid Pharma stock appears to be overvalued.
The current stock price of $5.45 is trading 18.5% above its estimated GF Value™ of $4.60.
Key valuation signals for LUX:ORCHP:
Cash Conversion Cycle: 117.32
GF Value™: $4.60 vs. price of $5.45 (18.5% above fair value)
Industry Position: 19.5% below the Drug Manufacturers median
No single metric tells the full story. See the LUX:ORCHP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Orchid Pharma Ltd is involved in the development, manufacturing, and marketing of diverse bulk actives, formulations, and nutraceuticals. The company operates in one business segment, which is Pharmaceuticals, in which the company derives its maximum sales through Active Pharmaceutical Ingredients. It produces various products such as tablets, injectables, and APIs for cardiovascular, anti-diabetic, neuropsychiatry, veterinary, non-antibiotic, and cephalosporins. The products are grouped under formulations and active pharmaceutical ingredients. Geographically, the company generates maximum revenue from the export of its products to international markets like the United States, Canada, Europe, Japan, Australia, and China etc., and the rest from its business in India.
60GF Score
Get the complete analysis for LUX:ORCHP
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LUX:ORCHP has been successfully added to your 
